These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37554894)

  • 21. Plasminogen activator inhibitor-1 is associated with coronary artery calcium in Type 1 diabetes.
    Pratte KA; Barón AE; Ogden LG; Hassell KL; Rewers M; Hokanson JE
    J Diabetes Complications; 2009; 23(6):387-93. PubMed ID: 18768333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship of tissue plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen with coronary artery disease in South Indian male subjects.
    Deepa R; Velmurugan K; Saravanan G; Dwarakanath V; Agarwal S; Mohan V
    J Assoc Physicians India; 2002 Jul; 50():901-6. PubMed ID: 12126344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Evolution of fibrinolysis status with D-dimer level and the rate of plasminogen activator inhibitor type-1/D-dimer in acute coronary syndrome patients complicated with impaired glucose tolerance].
    Wu WD; Xu YH; Tan PY
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2003 Aug; 15(8):472-5. PubMed ID: 12919647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in proliferative diabetic retinopathy: a pilot study.
    Simpson AJ; Booth NA; Moore NR; Lewis SJ; Gray RS
    Acta Diabetol; 1999 Sep; 36(3):155-8. PubMed ID: 10664320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence.
    Sobel BE; Woodcock-Mitchell J; Schneider DJ; Holt RE; Marutsuka K; Gold H
    Circulation; 1998 Jun; 97(22):2213-21. PubMed ID: 9631870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
    Kruszynska YT; Yu JG; Olefsky JM; Sobel BE
    Diabetes; 2000 Apr; 49(4):633-9. PubMed ID: 10871202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis.
    Sakurai S; Jojima T; Iijima T; Tomaru T; Usui I; Aso Y
    J Diabetes Complications; 2020 Nov; 34(11):107703. PubMed ID: 32883567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1.
    Aso Y; Matsumoto S; Fujiwara Y; Tayama K; Inukai T; Takemura Y
    Metabolism; 2002 Apr; 51(4):471-6. PubMed ID: 11912556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasminogen activator inhibitor-1 deficiency has renal benefits but some adverse systemic consequences in diabetic mice.
    Collins SJ; Alexander SL; Lopez-Guisa JM; Cai X; Maruvada R; Chua SC; Zhang G; Okamura DM; Matsuo S; Eddy AA
    Nephron Exp Nephrol; 2006; 104(1):e23-34. PubMed ID: 16735799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Fibrinolytic system in patients with myocardial infarction and other coronary disease risk factors].
    Moreno JA; Gálvez MM; Cornudella R; Angós JA; Romero MS; Gutiérrez M
    Sangre (Barc); 1994 Apr; 39(2):111-6. PubMed ID: 8059288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of plasminogen activator inhibitor-1, tissue type plasminogen activator antigen, fibrinogen, and D-dimer levels in various age decades in patients with type 2 diabetes mellitus and stable coronary artery disease (from the BARI 2D trial).
    McBane RD; Hardison RM; Sobel BE;
    Am J Cardiol; 2010 Jan; 105(1):17-24. PubMed ID: 20102884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Selected new atherosclerosis risk factors and markers of fibrinolysis in children and adolescents with obesity, hypertension and diabetes].
    Głowińska B; Urban M; Koput A; Galar M
    Przegl Lek; 2003; 60(1):12-7. PubMed ID: 12884639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients.
    Lindgren A; Lindoff C; Norrving B; Astedt B; Johansson BB
    Stroke; 1996 Jun; 27(6):1066-71. PubMed ID: 8650716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis.
    Etingin OR; Hajjar DP; Hajjar KA; Harpel PC; Nachman RL
    J Biol Chem; 1991 Feb; 266(4):2459-65. PubMed ID: 1824942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of type-1 plasminogen activator inhibitor in the kidney of diabetic rat models.
    Hagiwara H; Kaizu K; Uriu K; Noguchi T; Takagi I; Qie YL; Seki T; Ariga T
    Thromb Res; 2003; 111(4-5):301-9. PubMed ID: 14693179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor-1 in type 2 diabetic patients.
    Vukovich T; Proidl S; Knöbl P; Teufelsbauer H; Schnack C; Schernthaner G
    Thromb Haemost; 1992 Sep; 68(3):253-6. PubMed ID: 1440487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasminogen activator inhibitor (PAI-1) and non-insulin-dependent diabetes in Pima Indians, south Asians and Europeans. Populations at varying risk of NIDDM and coronary artery disease.
    Nagi DK; Knowler WC; Hanson RL; Ali VM; Yudkin JS
    Thromb Haemost; 1996 Jun; 75(6):921-7. PubMed ID: 8822587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of strict metabolic control by insulin infusion on fibrinolytic profile during an acute coronary event in diabetic patients.
    Melidonis A; Stefanidis A; Tournis S; Manoussakis S; Handanis S; Zairis M; Dadiotis L; Foussas S
    Clin Cardiol; 2000 Mar; 23(3):160-4. PubMed ID: 10761802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects.
    Pandolfi A; Cetrullo D; Polishuck R; Alberta MM; Calafiore A; Pellegrini G; Vitacolonna E; Capani F; Consoli A
    Arterioscler Thromb Vasc Biol; 2001 Aug; 21(8):1378-82. PubMed ID: 11498469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibrinolysis and lipoprotein(a) in women with coronary artery disease. Influence of hormone replacement therapy.
    Falcó C; Tormo G; Estellés A; España F; Tormo E; Gilabert J; Velasco JA; Aznar J
    Haematologica; 2001 Jan; 86(1):92-8. PubMed ID: 11146577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.